Special Offering :
Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
The Asia Pacific Needle-Free Injection System Market would witness market growth of 17% CAGR during the forecast period (2018 - 2024). Needle-free injection technology involves wide-ranging drug delivery systems which can drive drugs through the skin using forces like Lorentz, Shockwaves, pressure by gas, or electrophoresis. The process propels the drug to pass through the skin, and virtually nullifies the use of hypodermic needles.
The technology is highly beneficial in the pharma industry and also it is widely popular in the developing countries, as it is used in mass immunization programs, bypassing the chances of needle stick injuries and avoiding other complications including those arising due to multiple use of single needle. On the basis of Product, the market is segmented into Prefilled Needle-Free Injectors and Fillable Needle-Free Injectors. Technology is categorized into Jet-Based Needle-Free Injectors, Spring-Based Needle-Free Injectors, Laser-Powered Needle-Free Injectors, and Vibration-Based Needle-Free Injectors.
On the basis of Type, the market is segmented into Liquid-Based Needle-Free Injectors, Projectile/Depot-Based Needle-Free Injectors, and Powder-Based Needle Free Injectors. By Site of delivery, the market is divided into Subcutaneous Injectors, Intramuscular Injectors, and Intradermal Injectors. Usability has been segmented into Reusable Needle-Free Injectors and Disposable Needle-Free Injectors. On the basis of Application, the market is categorized into Vaccine Delivery, Insulin Delivery, Pain Management, and Other Applications.
The End Users covered under the report are Hospitals and Clinics, Home Care Settings, Research Laboratories, and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific. The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Endo International PLC, Antares Pharma, Inc, Pharmajet, Medical International Technology, Inc. (MIT), National Medical Product Inc, Valeritas Inc, European Pharma Group BV, Portal Instruments, Injex Pharma AG, Bioject Medical Technologies Inc.